Atlas Trials

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

Clinical trial NCT00135577 · COMPLETED

Trial details

NCT number
NCT00135577
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
CancerBowel Dysfunction
Start date
2004-09-01
Primary completion
2007-04-01
Enrollment
67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.